Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer

International Journal of Clinical Oncology

Volumn 14, Issue 1, 2009, Pages 63-69

  Shimokawa, Tsuneo ^a,b   Shibuya, Masahiko ^a   Kitamura, Kazuhiro ^a   Hosomi, Yukio ^a   Hibino, Suguru ^a   Ota, Tomohiro ^a   Iguchi, Mari ^a   Okamura, Tatsuru ^a   Gemma, Akihiko ^b  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Amrubicin; Dose; Refractory disease; Sensitive disease; Small cell lung cancer

Indexed keywords

AMRUBICIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; PACLITAXEL; TOPOTECAN;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LUNG SMALL CELL CANCER; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 60649090249     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-008-0802-2     Document Type: Article

References (33)

1. D.M. Jackman B.E. Johnson 2005 Small-cell lung cancer Lancet 366 1385 1396
2. G. Simon R.J. Ginsberg J.C. Ruckdeschel 2001 Small-cell lungcancer Chest Surg Clin N Am 11 165 188
3. G. Giaccone M. Donadio G. Bonardi 1998 Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy J Clin Oncol 6 1264 1270
4. J.R. Eckardt 2003 Second-line treatment of small-cell lung cancer. The case for systemic chemotherapy Oncology (Williston Park) 17 181 188
5. P.E. Postmus E.F. Smit A. Kirkpatrick 1993 Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC Lung Cancer Cooperative Group Eur J Cancer 29A 204 207
6. Y. Ohe K. Nakagawa Y. Fujiwara 1989 In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines Cancer Res 49 4098 4102
7. M. Hanada S. Mizuno A. Fukushima 1998 A new anticancer agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex Jpn J Cancer Res 89 1229 1238
8. T. Noda T. Watanabe A. Kohda 1998 Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs Invest New Drugs 16 121 128
9. T. Noguchi S. Ichii S. Morisada 1998 In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite Jpn J Cancer Res 89 1055 1060
10. T. Noguchi S. Ichii S. Morisada 1998 Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin Jpn J Cancer Res 89 1061 1066
11. T. Yamaoka M. Hanada S. Ichii 1998 Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells Jpn J Cancer Res 89 1067 1073
12. T. Yamaoka M. Hanada S. Ichii 1999 Uptake and intracellular distribution of amrubicin, a novel 9-amino-anthracycline, and its active metabolite amrubicinol in P388 murine leukemia cells Jpn J Cancer Res 90 685 690
13. N. Obara S. Imagawa Y. Nakano 2003 Hematological aspects of a novel 9-aminoanthracycline, amrubicin Cancer Sci 94 1104 1106
14. K. Ishizumi N. Ohashi N. Tanno 1987 Stereospecific total synthesis of 9-aminoanthracyclines: (+)-9-amino-9-deoxydaunomycin and related compounds J Org Chem 52 4477 4485
15. T. Yana S. Negoro Y. Takada 1998 Phase II study of amrubicin (SM-5887): a 9-amino-anthracycline, in previously untreated patients with extensive stage small-cell lung cancer (ES-SCLC) - A West Japan Lung Cancer Group Trial Proc Am Soc Clin Oncol 17 450a
16. P. Therasse S.G. Arbuck E.A. Eisenhauer 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216
17. E.L. Kaplan P. Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457 481
18. M.E.R. O'Brien T. Ciuleanu H. Tsekov 2006 Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer J Clin Oncol 24 5441 5447
19. J. von Pawel J.H. Schiller F.A. Shepherd 1999 Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer J Clin Oncol 17 658 667
20. N. Masuda M. Fukuoka Y. Kusunoki 1992 CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer J Clin Oncol 10 1225 1229
21. T. Le Chevalier N. Ibrahim P. Chomy 1997 A phase II study of irinotecan (CPT-11) in patients with small cell lung cancer progressing after initial response to first-line chemotherapy Proc Am Soc Clin Oncol 16 450a
22. R. DeVone C. Blanke C. Denham 1998 Phase II study of irinotecan (CPT-11) in patients with previously treated small-cell lung cancer Proc Am Soc Clin Oncol 17 451a
23. A. Ardizzoni H. Hansen P. Dombernowsky 1997 Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease - The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development office, and the Lung Cancer Cooperative Group J Clin Oncol 15 2090 2096
24. E.F. Smit E. Fokkema B. Biesma 1998 A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer Br J Cancer 77 347 351
25. S. Tsukiyama N. Yamamoto H. Uejima 2001 Phase II study of weekly paclitaxel in platinum-treated patients with small cell lung cancer Proc Am Soc Clin Oncol 20 281b
26. J.F. Smyth I.E. Smith C. Sessa 1994 Activity of docetaxel (Taxotere) in small cell lung cancer: The Early Clinical Trials Group of the EORTC Eur J Cancer 30A 1058 1060
27. G.A. Masters L. Declerck C. Blanke 2003 Eastern Cooperative Oncology Group: phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597 J Clin Oncol 21 1550 1555
28. I. van der Lee E.F. Smit J.W. van Putten 2001 Single-agent gemcitabine in patients with resistant small-cell lung cancer Ann Oncol 12 557 561
29. J. Jassem H. Karnick-Mlodkowska C. van Pottelsberghe 1993 Phase II study of vinorelbine (Naverbine) in previously treated small cell lung cancer patients: EORTC Lung Cancer Cooperative Group Eur J Cancer 29A 1720 1722
30. K. Furuse K. Kubota M. Kawahara 1996 Phase II study of vinorelbine in heavily previously treated small cell lung cancer patients: Japan Lung Cancer Vinorelbine Study Group Oncology 53 169 172
31. A. Kurup N.H. Hanna 2004 Treatment of small cell lung cancer Crit Rev Oncol Hematol 52 117 126
32. Y. Ohe S. Negoro K. Matsui 2005 Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer Ann Oncol 16 430 436
33. S. Onoda N. Masuda T. Seto 2006 Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301 J Clin Oncol 24 5448 5453